Methods in comparative effectiveness research
- PMID: 23071240
- PMCID: PMC3504326
- DOI: 10.1200/JCO.2012.42.2659
Methods in comparative effectiveness research
Abstract
Comparative effectiveness research (CER) seeks to assist consumers, clinicians, purchasers, and policy makers to make informed decisions to improve health care at both the individual and population levels. CER includes evidence generation and evidence synthesis. Randomized controlled trials are central to CER because of the lack of selection bias, with the recent development of adaptive and pragmatic trials increasing their relevance to real-world decision making. Observational studies comprise a growing proportion of CER because of their efficiency, generalizability to clinical practice, and ability to examine differences in effectiveness across patient subgroups. Concerns about selection bias in observational studies can be mitigated by measuring potential confounders and analytic approaches, including multivariable regression, propensity score analysis, and instrumental variable analysis. Evidence synthesis methods include systematic reviews and decision models. Systematic reviews are a major component of evidence-based medicine and can be adapted to CER by broadening the types of studies included and examining the full range of benefits and harms of alternative interventions. Decision models are particularly suited to CER, because they make quantitative estimates of expected outcomes based on data from a range of sources. These estimates can be tailored to patient characteristics and can include economic outcomes to assess cost effectiveness. The choice of method for CER is driven by the relative weight placed on concerns about selection bias and generalizability, as well as pragmatic concerns related to data availability and timing. Value of information methods can identify priority areas for investigation and inform research methods.
Conflict of interest statement
Author's disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures
Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Some methodological points to consider when performing systematic reviews in comparative effectiveness research.Clin Trials. 2012 Feb;9(1):27-34. doi: 10.1177/1740774511427062. Epub 2011 Nov 2. Clin Trials. 2012. PMID: 22049086
-
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research.Genet Med. 2012 Jul;14(7):633-42. doi: 10.1038/gim.2012.16. Genet Med. 2012. PMID: 22516979 Free PMC article. Review.
-
An overview of methods for comparative effectiveness research.Semin Radiat Oncol. 2014 Jan;24(1):5-13. doi: 10.1016/j.semradonc.2013.09.002. Semin Radiat Oncol. 2014. PMID: 24314337 Review.
Cited by
-
Clinical data mining: challenges, opportunities, and recommendations for translational applications.J Transl Med. 2024 Feb 20;22(1):185. doi: 10.1186/s12967-024-05005-0. J Transl Med. 2024. PMID: 38378565 Free PMC article. Review.
-
Comparing the evidence for botulinum neurotoxin injections in paediatric anterior drooling: a scoping review.Eur J Pediatr. 2024 Jan;183(1):83-93. doi: 10.1007/s00431-023-05309-1. Epub 2023 Nov 4. Eur J Pediatr. 2024. PMID: 37924348 Free PMC article. Review.
-
Association between adjuvant radiation treatment and breast cancer-specific mortality among older women with comorbidity burden: A comparative effectiveness analysis of SEER-MHOS.Cancer Med. 2023 Sep;12(18):18729-18744. doi: 10.1002/cam4.6493. Epub 2023 Sep 14. Cancer Med. 2023. PMID: 37706222 Free PMC article.
-
Immunochemotherapy or chemotherapy alone in primary central nervous system lymphoma: a National Cancer Database analysis.Blood Adv. 2023 Sep 26;7(18):5470-5479. doi: 10.1182/bloodadvances.2023010352. Blood Adv. 2023. PMID: 37459209 Free PMC article.
-
Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn's disease.World J Gastroenterol. 2023 May 14;29(18):2784-2797. doi: 10.3748/wjg.v29.i18.2784. World J Gastroenterol. 2023. PMID: 37274072 Free PMC article. Review.
References
-
- Committee on Comparative Effectiveness Research Prioritization, Institute of Medicine: Washington, DC: The National Academies Press; 2009. Summary: Initial National Priorities for Comparative Effectiveness Research; p. 29.
-
- Berwick DM, Nolan TW, Whittington J. The triple aim: Care, health, and cost. Health Aff (Millwood) 2008;27:759–769. - PubMed
-
- Brook RH. Can the Patient-Centered Outcomes Research Institute become relevant to controlling medical costs and improving value? JAMA. 2011;306:2020–2021. - PubMed
-
- Federal Coordinating Council: Report to the President and the Congress on Comparative Effectiveness Research. http://www.hhs.gov/recovery/programs/cer/execsummary.html.
-
- Sox HC, Goodman SN. The methods of comparative effectiveness research. Annu Rev Public Health. 2012;33:425–445. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
